BLUE BELL, Pa. , June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Brian Di Donato , Chief Financial
BLUE BELL, Pa. , June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa. , May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated
USPTO grants composition of matter patent for ACH-5548, Achillion’s 3rd clinical-stage asset BLUE BELL, Pa. , May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families
- PNH combo Phase 2 trial interim data to be presented May 17, 2019 - - C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 - - Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa.
- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa. , April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa. , March 27, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa. , March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND anticipated in Q4:2019 - - Reduced 2018 net cash spend to $60 million , projecting $80
NEW HAVEN, Conn. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office